These findings suggest that tRF-3009 may contribute to SLE pathogenesis by regulating CD4+ T cell metabolic pathways, thus providing a novel target for SLE treatment (Geng et al., 2021). This evidence concerns the gene CD4 and systemic lupus erythematosus.